Cochrane · systematic review · CD008516
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow‐responder adult patients
Katz, LH, Goldvaser, H, Gafter‐Gvili, A, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 42.9%Low 3 · 42.9%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow responders
Population: participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral reduction, and undetectable HCV RNA after 24 weeks of treatment.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sustained virological response (SVR) Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 1.43 | 5 studies · 411 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 0.59 | 3 studies · 175 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
End of treatment response (ETR) Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 0.96 | 3 studies · 334 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow responders
Population: participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sustained virological response (SVR) Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 1.27 | 3 studies · 995 participants | Low Downgraded: risk of bias, indirectness |
Relapse rate Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 0.59 | 3 studies · 703 participants | Low Downgraded: risk of bias, indirectness |
End of treatment response (ETR) Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 0.99 | 3 studies · 995 participants | Low Downgraded: risk of bias, indirectness |
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow responders
Population: participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin or participants with detectable HCV RNA after 12 weeks of treatment, but with >= 2 log viral reduction, and undetectable HCV RNA after 24 weeks of treatment.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adherance to treatment Extended peginterferon plus ribavirin treatment for 72 weeks vs standard peginterferon plus ribavirin treatment | RR 0.95 | 2 studies · 260 participants | Moderate Downgraded: risk of bias |